Viatris Net Long-Term Debt 2010-2025 | VTRS
Viatris annual/quarterly net long-term debt history and growth rate from 2010 to 2025. Net long-term debt can be defined as the net amount of long term debt issued and repaid. This field is either calculated as the sum of the long term debt fields or used if a company does not report debt issued and repaid separately
- Viatris net long-term debt for the quarter ending March 31, 2025 was $0M, a 0% increase year-over-year.
- Viatris net long-term debt for the twelve months ending March 31, 2025 was $-6.855B, a 149.26% increase year-over-year.
- Viatris annual net long-term debt for 2024 was $-3.714B, a 197.12% increase from 2023.
- Viatris annual net long-term debt for 2023 was $-1.25B, a 30.05% decline from 2022.
- Viatris annual net long-term debt for 2022 was $-1.787B, a 28.27% decline from 2021.
| Viatris Annual Net Long-Term Debt (Millions of US $) |
|
|---|---|
| 2024 | $-3,714 |
| 2023 | $-1,250 |
| 2022 | $-1,787 |
| 2021 | $-2,491 |
| 2020 | $-1,501 |
| 2019 | $-1,101 |
| 2018 | $-587 |
| 2017 | $-1,357 |
| 2016 | $5,456 |
| 2015 | $1,026 |
| 2014 | $-61 |
| 2013 | $1,494 |
| 2012 | $53 |
| 2011 | $-186 |
| 2010 | $241 |
| 2009 | $-344 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $10.481B | $14.739B |
| Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $138.024B | 25.89 |
| CVS Health (CVS) | United States | $80.885B | 10.05 |
| Elevance Health (ELV) | United States | $75.961B | 9.80 |
| Cencora (COR) | United States | $57.110B | 19.87 |
| DiDi Global (DIDIY) | China | $25.792B | 27.40 |
| Labcorp Holdings (LH) | United States | $20.561B | 16.68 |
| Natera (NTRA) | United States | $20.462B | 0.00 |
| BioMerieux (BMXMF) | France | $16.861B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $13.598B | 0.00 |
| CochLear (CHEOY) | Australia | $12.760B | 0.00 |
| Solventum (SOLV) | United States | $12.748B | 13.49 |
| ICON (ICLR) | Ireland | $11.757B | 10.93 |
| Revvity (RVTY) | United States | $11.304B | 19.45 |
| Medpace Holdings (MEDP) | United States | $8.988B | 23.87 |
| Sonic Healthcare (SKHHY) | Australia | $8.788B | 0.00 |
| Avantor (AVTR) | United States | $8.736B | 12.69 |
| HealthEquity (HQY) | United States | $8.317B | 36.43 |
| Charles River Laboratories (CRL) | United States | $7.584B | 14.86 |
| Caris Life Sciences,�Inc (CAI) | United States | $7.355B | 0.00 |
| Amplifon S.p.A (AMFPF) | Italy | $5.378B | 29.44 |
| Bausch + Lomb (BLCO) | Canada | $4.851B | 28.56 |
| BrightSpring Health Services (BTSG) | United States | $3.527B | 32.35 |
| Sotera Health (SHC) | United States | $3.230B | 18.35 |
| Surgery Partners (SGRY) | United States | $2.799B | 36.40 |
| Alignment Healthcare (ALHC) | United States | $2.623B | 0.00 |
| Concentras Parent (CON) | United States | $2.543B | 14.70 |
| Organon (OGN) | United States | $2.485B | 2.64 |
| GeneDx Holdings (WGS) | United States | $2.331B | 89.77 |
| Progyny (PGNY) | United States | $1.992B | 43.85 |
| Ardent Health (ARDT) | United States | $1.991B | 8.49 |
| PACS (PACS) | United States | $1.897B | 0.00 |
| Premier (PINC) | United States | $1.719B | 13.05 |
| GoodRx Holdings (GDRX) | United States | $1.697B | 33.93 |
| Teladoc Health (TDOC) | United States | $1.388B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.285B | 0.00 | |
| Pediatrix Medical (MD) | United States | $1.100B | 8.37 |
| CareDx (CDNA) | United States | $1.058B | 16.53 |
| Ryman Healthcare (RYHTY) | New Zealand | $0.970B | 0.00 |
| Agilon Health (AGL) | United States | $0.911B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.848B | 291.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.761B | 7.13 |
| Nutex Health (NUTX) | United States | $0.632B | 9.57 |
| InnovAge Holding (INNV) | United States | $0.564B | 0.00 |
| Embecta (EMBC) | United States | $0.560B | 3.77 |
| SBC Medicals (SBC) | United States | $0.511B | 0.00 |
| LifeMD (LFMD) | United States | $0.497B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.473B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.472B | 10.63 |
| Omada Health (OMDA) | $0.463B | 0.00 | |
| So-Young (SY) | China | $0.455B | 0.00 |
| Enhabit (EHAB) | United States | $0.354B | 29.17 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.333B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.309B | 0.00 |
| Oncology Institute (TOI) | United States | $0.265B | 0.00 |
| Beauty Health (SKIN) | United States | $0.207B | 0.00 |
| DocGo (DCGO) | United States | $0.142B | 23.17 |
| Pheton Holdings (PTHL) | China | $0.136B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.102B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.072B | 0.00 |
| KindlyMD (NAKA) | United States | $0.071B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.059B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.047B | 0.00 |
| Biodesix (BDSX) | United States | $0.045B | 0.00 |
| ModivCare (MODV) | United States | $0.045B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.035B | 0.00 |
| OSR Holdings (OSRH) | United States | $0.020B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.013B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.009B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.007B | 0.00 | |
| SeaStar Medical Holding (ICU) | United States | $0.006B | 0.00 |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.003B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |